By Alice Goodman Posted: 10/19/2021 2:16:00 PM Last Updated: 10/19/2021 2:13:29 PM Rechallenge with the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in patients with platinum-sensitive ovarian cancer led to significant improvement in progression-free survival, in…
Allison Betof Warner, MD, PhD, reviews important clinical research in the treatment of advanced melanoma, including tumor-infiltrating lymphocyte (TIL) therapy, the role of this innovative…
OCE Insights is developed for The ASCO Post by members of the Oncology Center of Excellence (OCE) at the FDA. In this installment, the authors…
Aditya Bardia, MD, of UCLA David Geffen School of Medicine, Los Angeles, presents the additional analysis of the efficacy and safety of trastuzumab deruxtecan vs…
OCE Insights is developed for The ASCO Post by members of the Oncology Center of Excellence (OCE) at the FDA. In this installment, the authors…
Matthew S. Davids, MD, MMSc, of Dana-Farber Cancer Institute, Boston, discusses the primary endpoint evaluation of a phase II trial of the triplet regimen of…
The American Society of Clinical Oncology elected Elizabeth A. Mittendorf, MD, PhD, MHCM, FASCO, to lead as its President beginning in June 2026. Dr. Mittendorf,…
Nikolaos Katsivelos, MD, and John Levine, MD, MS, of Icahn School of Medicine at Mount Sinai report on an investigation into the potential for serial…
Kathryn Newlin, RN, MSN, ANP-BC, of Washington University in St. Louis, discusses her presentation on HR+ HER2- metastatic breast cancer from the JADPRO Live conference…
Ellen V. Sigal, founder of Friends of Cancer Research, reflects on her recent cancer diagnosis and the need to ensure that all patients can access…
Danielle Wolfe Cohen, MD, of the William L. Carroll Laboratory at New York University Grossman School of Medicine, describes data illuminating the role of an…
